Clinical Trial Outcomes and Efficacy Failure: The ongoing Phase 3 trial for losmapimod in FSHD or other clinical programs may not achieve their primary endpoints, demonstrate sufficient efficacy, or prove to be acceptably safe, leading to program delays, abandonment, or negative investor perception.

Regulatory Approval Uncertainty: Even with successful clinical trial data, there is no guarantee that regulatory authorities like the FDA will grant marketing approval for any of Fulcrum's product candidates, which could prevent or significantly delay commercialization.

Intense Competitive Landscape: Fulcrum faces substantial competition from other pharmaceutical and biotechnology companies developing treatments for FSHD, sickle cell disease, and other target indications, which could impact market share, pricing power, and commercial success.